Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy

Walter Reed Army Medical Center

Status

Completed

Conditions

Postoperative Pain

Treatments

Drug: Gabapentin

Drug: placebo

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT00793910

WRAMC WU# 08-6960

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of an oral medication called gabapentin in reducing pain after Photorefractive Keratectomy (PRK) eye surgery and to assess the frequency of use of rescue medication interventions, defined as non-steroidal anti-inflammatory (NSAID) eye drops and oral narcotic medication.

Enrollment

106 patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Ability to understand and provide informed consent to participate in this study and complete follow-up visits.
Planned Photorefractive keratectomy (PRK) at the WRAMC Center for Refractive Surgery.
Male or female, of any race, and at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
Access to transportation to meet follow-up requirements.

Exclusion criteria

Any reason to be excluded for PRK.
Female subjects who are pregnant, breast feeding or intend to become pregnant during the study. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy. [Pregnancy and breastfeeding are contraindications to refractive surgery in general, including PRK, whether participating in this study or not].
Patients with known allergy, sensitivity or inappropriate responsiveness to Gabapentin or any of the medications used in the post-operative course.
Patients with known depressed renal function.
Any physical or mental impairment that would preclude participation in any of the examinations.